In a high-stakes pivot toward the lucrative American medical device market, Nyxoah SA has announced a significant leadership transition. Effective October 1, 2026, industry veteran Liam Kelly will step into the role of Chief Executive Officer (CEO), succeeding Olivier Taelman. This move signals a deliberate shift in strategy as the company looks to capitalize on the recent FDA approval and early-stage commercial rollout of its flagship Genio hypoglossal neurostimulation system for the treatment of obstructive sleep apnea (OSA).
The transition occurs at a critical juncture for the Belgium-based company. With the Genio system—a breakthrough, battery-free, and bilateral neurostimulation therapy—now entering the US clinical landscape, Nyxoah is moving from a research-and-development-focused entity to a high-growth commercial enterprise.
The Strategic Shift: A Focus on US Commercialization
The appointment of Liam Kelly is widely viewed by industry analysts as a tactical move to bolster Nyxoah’s presence in the United States. Kelly, who previously served as the chairman, president, and CEO of Teleflex Incorporated until early 2026, brings a wealth of experience in navigating the complexities of the US healthcare market. His tenure at Teleflex, combined with a decade of senior leadership roles at Hill-Rom Holdings Inc, provides him with the institutional knowledge required to scale a medical technology firm in an increasingly competitive space.
The Genio system represents a novel approach to OSA, using bilateral stimulation of the hypoglossal nerve to prevent airway collapse during sleep. Unlike traditional CPAP machines, which often suffer from poor patient compliance, or unilateral neurostimulation devices, Genio offers a more precise, patient-centric intervention.
“The US launch is still in its early stages,” Kelly noted in an official release. “The momentum we are seeing in physician adoption gives me great confidence in what lies ahead. Genio is a truly differentiated technology in the treatment of sleep apnea, and it has tremendous potential to impact patient lives globally.”
Chronology of a Corporate Evolution
The path to this leadership transition has been paved by a series of regulatory and operational milestones that have redefined Nyxoah’s corporate trajectory over the last 24 months:
- Mid-2025: Nyxoah ramps up clinical data collection to support its Pre-Market Approval (PMA) application with the US Food and Drug Administration (FDA).
- Early 2026: The company receives FDA approval for the Genio system, marking its official entry into the world’s largest market for sleep apnea therapies.
- Q2 2026: The first commercial patients are successfully implanted with the Genio system in the United States, signaling the start of the "market education" phase.
- September 2026: Nyxoah formally announces the departure of Olivier Taelman and the appointment of Liam Kelly as CEO, effective October 1.
- October 2, 2026: CFO John Landry announces his resignation, triggering a transition in financial leadership.
Financial Implications and Executive Turnover
While the focus remains on commercial growth, the company also faces the challenges of maintaining financial stability during a period of executive turnover. CFO John Landry, who has been a cornerstone of the company’s financial strategy, is set to step down on October 2, 2026. Landry is departing to join CVRx Inc, a commercial-stage medical device company focused on cardiovascular neuromodulation, where he will assume the CFO role on October 12, succeeding Jared Oasheim.
To ensure continuity, Loïc Moreau, the company’s president of international operations and former CFO, will step in as interim CFO while the board conducts a search for a permanent successor.
Despite these departures, Nyxoah has moved quickly to reassure investors, explicitly reaffirming its previously issued financial guidance for the full year 2026. This reaffirmation is critical for maintaining market confidence as the company burns capital to fund its aggressive sales and marketing push across US hospitals and sleep clinics.
Supporting Data: The Market Opportunity for Genio
The rationale for this leadership shift is grounded in the sheer size of the sleep apnea market. Obstructive Sleep Apnea affects millions of Americans, many of whom are either intolerant of CPAP therapy or are looking for long-term surgical alternatives.
The Genio system’s "differentiated" value proposition—its bilateral stimulation approach—is designed to provide a more natural, balanced expansion of the airway. By focusing on the US, Nyxoah is targeting the largest reimbursement pool for sleep apnea devices in the world.
According to recent industry data:
- Physician Adoption: Early feedback from implanting physicians suggests that the surgical procedure for Genio is intuitive, which lowers the barrier to entry for surgeons trained in existing neurostimulation techniques.
- Patient Compliance: Because the device is an internal implant, it eliminates the "mask fatigue" associated with CPAP, a factor that historically leads to high discontinuation rates.
- Market Expansion: With the FDA approval now in hand, Nyxoah is positioned to compete directly with existing market leaders, potentially capturing significant market share in the neurostimulation segment.
Official Responses and Stakeholder Perspectives
Robert Taub, chairman of Nyxoah, emphasized that the decision to bring in an executive with Kelly’s pedigree was driven by the need for operational scaling. "The US is at the center of our growth strategy," Taub said. "Liam is a seasoned US medtech executive with a strong track record of scaling organizations, driving commercial performance, and creating shareholder value."
The transition, while significant, is viewed as a natural progression for a company that has successfully navigated the "Valley of Death"—the difficult phase where a medical device company moves from experimental development to commercial revenue.
Investors have reacted with a mix of cautious optimism. The resignation of the CFO is often a point of concern for market analysts, but the swift appointment of an interim replacement with deep internal knowledge (Moreau) has helped mitigate volatility. The primary focus for the market in the coming quarters will be the "take-up rate" of Genio in the US market, specifically how many new centers begin offering the procedure under Kelly’s guidance.
Implications: The Future of Neurostimulation
As the healthcare sector shifts toward personalized, tech-driven therapies, the success of the Genio system could redefine the treatment algorithm for OSA. If Kelly can successfully execute the commercial rollout, Nyxoah may become a primary target for acquisition or a dominant independent player in the neuromodulation space.
Key Objectives for the New Leadership:
- Sales Force Expansion: Building a robust US-based sales team capable of educating surgeons and hospital administrators.
- Reimbursement Strategy: Ensuring that Genio is included in major private and public insurance coverage plans to facilitate patient access.
- Clinical Differentiation: Continued publication of long-term clinical data to support the efficacy of bilateral stimulation against competitor products.
In conclusion, Nyxoah stands at a crossroads. By installing Liam Kelly at the helm, the company has made it clear that the "research" phase is behind them. The mission for the next three years is purely commercial: to turn a breakthrough European-born technology into a standard-of-care solution for millions of American patients suffering from sleep-disordered breathing. Whether the company can maintain its internal momentum while navigating these high-level executive changes remains the defining question for the remainder of 2026 and beyond.
